Objective: This study aims to investigate the viability and safety of utilizing ropinirole in combination with nerve growth factor for the management of neurological health in football players.

Methods: A total of 92 athletic inpatients diagnosed with Parkinson's disease were enrolled in this study from December 2018 to December 2020. They were randomly divided into two groups: the control group and the research group, each comprising 46 athletic patients. The control group received nerve growth factor treatment, while the research group received a combination of ropinirole and nerve growth factor. Various serum markers, brain nerve factors, quality of life indicators, therapeutic outcomes, and safety profiles were evaluated and compared between the two groups.

Results: Following treatment, both groups exhibited a significant increase in superoxide dismutase (SOD) levels compared to baseline, accompanied by substantial reductions in the levels of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and nuclear factor-kappa B P65 (NF-κB P65). Moreover, the research group demonstrated significantly higher SOD levels and lower IL-1β, TNF-α, and NF-κB P65 levels compared to the control group (P<0.05). The levels of ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), dopamine (DA), and serotonin (5-HT) significantly increased in both groups post-treatment, with the research group exhibiting notably higher levels of these factors compared to the control group (P<0.05). Assessment of cognitive function (Montreal Cognitive Assessment - MoCA), balance (Berg Balance Scale - BBS), and activities of daily living (ADL) scores revealed significant improvements in both groups after treatment. However, the research group displayed higher MoCA and BBS scores and lower ADL scores than the control group (P<0.05). The total effective rate in the research group (95.65%) was significantly higher than that in the control group (82.61%) after treatment (P<0.05). Furthermore, no abnormalities were detected in ECG, routine hematuria, biochemical analyses, liver and kidney function, or head MRI in either group. The incidence of adverse reactions in the research group (8.70%) was considerably lower than that in the control group (17.39%).

Conclusion: The combination of ropinirole and nerve growth factor for the management of Parkinson's disease demonstrates potential in enhancing immune function, increasing brain nerve factor levels, improving the quality of life, and enhancing treatment outcomes. This approach appears to be both feasible and safe, providing valuable data for the clinical management of Parkinson's disease in football players and fitness enthusiasts.